Natural course of experimental retinal vein occlusion in rabbit; arterial occlusion following venous photothrombosis

Ameri, Hossein; Ratanapakorn, Tanapat; Rao, Narsing A.; Chader, Gerald J.; Humayun, Mark S.

doi:10.1007/s00417-008-0878-4

Cited by 30 publications

(41 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 The point is that the transient elevation of the VEGF protein level just after the photocoagulation can be suppressed by medical drugs, and Although the retinal vessels of rabbits have some anatomical differences when compared with those of humans, 17 the pathological effects of the rabbit RVO model is expected to be similar to humans. 9 If the findings in our data using experimental models are confirmed in humans, a better way to treat vascular pathology of retina would be set in clinical practice. However, we are not able to obtain the retinal or choroidal tissue from the patients with vein occlusion.…”

Section: -6mentioning

confidence: 96%

“…Optical coherence tomography, which provides a crosssectional retinal image with high resolution, is used for not only clinical examination but also the experiments using animal models. 9,[18][19][20] However, it was difficult for us to detect a subtle change of retinal tissue after the venous occlusion (data not shown). In this study, therefore, we could not get more detailed findings using optical coherence tomography than histological examination and in situ hybridization.…”

Section: -6mentioning

confidence: 99%

“…9 For the expected NPAs of RVO eyes, laser photocoagulation was performed (532 nm, 100 mW, 200 ms, 400 spots) simultaneously with RVO creation.…”

Section: Rvo Creation and Laser Photocoagulation Of Npasmentioning

confidence: 99%

See 2 more Smart Citations

Photocoagulation of the Retinal Nonperfusion Area Prevents the Expression of the Vascular Endothelial Growth Factor in an Animal Model

Gozawa

Takamura

Miyake

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. The purpose of this study was to evaluate whether photocoagulation of the retinal nonperfusion area suppresses ocular vascular endothelial growth factor (VEGF) expression in a rabbit retinal vein occlusion (RVO) model. METHODS.The retinas of pigmented rabbits were made ischemic by a laser on the main branch of retinal veins following intravenous injection of Rose Bengal. The eyes were enucleated before treatment and at 1, 7, and 14 days after laser occlusion. VEGF protein levels in the vitreous humor, sensory retina, and retinal pigment epithelium-choroid were measured with enzyme-linked immunosorbent assay. In situ hybridization of VEGF messenger RNA was performed to detect the location of VEGF expression in the sensory retina.RESULTS. In the vitreous body, the VEGF protein level in the RVO group, but not that in the RVO þ panretinal photocoagulation group, significantly increased on day 14. In the retina, the VEGF protein level in the RVO þ panretinal photocoagulation group was significantly higher than that in the RVO group on day 1, but was significantly lower than that in the RVO group on days 7 and 14. In the in situ hybridization analysis, the RVO group showed a high expression of VEGF in the inner nuclear and ganglion cell layers on days 7 and 14. In contrast, VEGF expression in the RVO þ panretinal photocoagulation group was strongly suppressed in both the inner nuclear and ganglion cell layers on days 7 and 14.CONCLUSIONS. This study is the first using an animal RVO model to demonstrate that laser photocoagulation of the retinal nonperfusion area suppresses VEGF-A expression in the retina.

show abstract

Section: -6mentioning

confidence: 96%

Section: -6mentioning

confidence: 99%

See 1 more Smart Citation

Photocoagulation of the Retinal Nonperfusion Area Prevents the Expression of the Vascular Endothelial Growth Factor in an Animal Model

Gozawa

Takamura

Miyake

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…Though laser-induced retinal vein occlusion is a common experimental model of CRVO, there are some differences to clinical conditions. One limitation of the model is the tendency to spontaneous recanalization [22,23]. Therefore, only tissues from animals, in which CRVO was confirmed in fluorescein angiography before the animals were killed, were used for the PCR analyses.…”

Section: Discussionmentioning

confidence: 99%

Effects of intravitreal triamcinolone acetonide on retinal gene expression in a rat model of central retinal vein occlusion

Rehák

Drechsler

Köferl

et al. 2011

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Zhang et al indicated that in laser-induced RVO in rat models, significant ganglion cell layer cell loss is associated with the pathogenesis of RVO [134]. On the other hand, Ameri et al suggested that the natural course of experimentally created RVO in rabbits was different from that in human [135]. Thus, it still seems to be difficult to obtain the basic evidence for the neuroprotective therapies for RGC death in RVO.…”

Section: Challenge To Neuroprotective Therapies For Dr and Rvomentioning

confidence: 91%

Diabetes Mellitus and Retinal Vein Occlusion as Risk Factors for Open Angle Glaucoma and Neuroprotective Therapies for Retinal Ganglion Cell Neuropathy

Bikbova¹,

Oshitari²,

Yamamoto³

2011

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

of glaucoma (NTG), and the prevalence of NTG is 3.6% in patients >40-years-of-age in Japan [10]. The average intraocular pressure (IOP) in patients with POAG is 15.4 ± 2.8 mmHg, which is significantly higher than that of normal subjects (14.5 ± 2.5 mmHg) [1][2][3][4][5][6][7][8][9][10] even though the average difference in the IOP is only 0.9 mmHg. Thus, a reduction of the IOP the standard therapy for glaucoma may not be sufficient for the complete management of the patients with glaucoma in Japan. Other therapeutic modalities, such as neuroprotection, should be considered for a complete therapeutic regimen for glaucoma patients.RGC death and axonal degeneration are most likely involved in the progression of DR, RVO, and glaucoma. Many neuroprotective therapies that prevent RGC death and axonal degeneration have been and are being investigated, and some of these neuroprotective factors may be used clinically in the near future. To establish neuroprotective therapies for DR, RVO and glaucoma, a determination of the exact mechanism that leads to a progression of RGC neuropathy to death and axonal degeneration is required [11]. However, the pathogenesis of the onset and progression of RGC neuropathy has still not been definitively determined. Identification of the risk factors for the onset and the progression of disease would help in determining the Abstract Glaucoma, diabetic retinopathy (DR), and retinal vein occlusion (RVO) are major diseases that can lead to blindness and affect mainly the elderly population worldwide. The results of recent investigations have demonstrated that the death of retinal ganglion cells (RGCs) and their axons is the common pathological change in these three disease processes. The exact mechanism that is responsible for the onset and progression of RGC death and axonal degeneration in patients with glaucoma, DR and RVO has not been definitively determined. Thus, identifying the risk factors for the onset and the progression of RGC neuropathy can help in deciding not only the specific treatments but also whether the treatments should be initiated, withheld, or augmented in individuals with glaucoma, DR, and RVO. This review describes the major risk factors for the onset of glaucoma, and the factors associated with the progression of glaucoma that have been obtained from large population-based prevalence and incidence studies. In addition, the potential risk factors for glaucoma, diabetes mellitus, and RVO are discussed in terms of the results obtained by both clinical and laboratory studies. This review introduces potential neuroprotective therapies for damaged RGC in eyes with RGC neuropathy, and the factors that should be considered for a complete therapy for the RGC neuropathy involved in glaucoma, DR and RVO. Neuroprotective therapies combined with a reduction of the IOP should be considered for the complete management of RGC neuropathy involved in glaucoma,

show abstract

Natural course of experimental retinal vein occlusion in rabbit; arterial occlusion following venous photothrombosis

Cited by 30 publications

References 16 publications

Photocoagulation of the Retinal Nonperfusion Area Prevents the Expression of the Vascular Endothelial Growth Factor in an Animal Model

Photocoagulation of the Retinal Nonperfusion Area Prevents the Expression of the Vascular Endothelial Growth Factor in an Animal Model

Effects of intravitreal triamcinolone acetonide on retinal gene expression in a rat model of central retinal vein occlusion

Diabetes Mellitus and Retinal Vein Occlusion as Risk Factors for Open Angle Glaucoma and Neuroprotective Therapies for Retinal Ganglion Cell Neuropathy

Contact Info

Product

Resources

About